TB-500

Tissue Repair & HealingMixed Availability

Solid research foundation with consistent findings across 30 studies, though the lack of rigorous human trials limits definitive clinical conclusions. The evidence strongly supports its biological mechanisms, but more controlled human studies are needed.

Primarily investigated by researchers studying cardiac repair, orthopedic injuries, and wound healing in both veterinary and human medicine contexts.

FDA Status

Banned from Compounding

Since Mar 2024

Evidence

Strong

Studies

30 total, 4 human

Popularity

#14 most researched

What is TB-500?

Derived from a naturally occurring protein found in wound healing, this synthetic peptide has become a cornerstone of regenerative medicine research. TB-500 mimics thymosin beta-4's cellular repair functions and attracts researchers studying everything from cardiac injury to muscle tears. Its reputation for promoting healing across multiple tissue types has made it one of the most investigated compounds in tissue engineering.

TB-500 works by binding to and organizing actin filaments, the structural proteins that form a cell's skeleton and enable movement. When tissues are damaged, this peptide helps cells migrate to injury sites more effectively while stimulating the formation of new blood vessels to supply nutrients. Think of it as a cellular traffic controller that directs repair crews to the right locations while ensuring adequate supply lines are established.

What the Research Shows

While 30 studies provide substantial mechanistic understanding, the absence of randomized controlled trials and limited human data (only 4 human studies) represents a significant evidence gap.

The clinical evidence base for TB-500 consists of 30 total studies, including 18 human studies but zero randomized controlled trials. Key findings indicate thymosin beta-4 functions as an actin-sequestering peptide that supports wound healing and modulates inflammation, with one study reporting 87.5% of patients achieved knee pain relief when thymosin beta-4 was combined with BPC-157 injection.